✦ LIBER ✦

Estrogen, progesterone, and androgen-binding sites in renal cell carcinoma. Observations obtained in phase II trial of flutamide

✍ Scribed by Tauseef Ahmed; Pasquale Benedetto; Alan Yagoda; Robin C. Watson; Howard I. Scher; Harry W. Herr; Pramod C. Sogani; Willet F. Whitmore; Louis Pertschuk

Publisher: John Wiley and Sons
Year: 1984
Tongue: English
Weight: 479 KB
Volume: 54
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19840801)54:3<477::aid-cncr2820540316>3.0.co;2-k

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Vinblastine and estramustine phosphate i

Vinblastine and estramustine phosphate in metastatic renal cell carcinoma : A phase II trial of the Fox Chase Network

✍ Naomi B. Haas; Bruce J. Giantonio; Samuel Litwin; Carl J. Minniti Jr.; Stephen F 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB 👁 1 views

## Abstract ## BACKGROUND It is well known that metastatic renal cell carcinoma (RCC) exhibits constitutive resistance to chemotherapeutic agents. Antimicrotubule agents such as vinblastine are associated with low but reproducible response rates (approximately 12%) in patients with RCC. Estramusti

Phase II trial of subcutaneously adminis

Phase II trial of subcutaneously administered granulocyte-macrophage colony-stimulating factor in patients with metastatic renal cell carcinoma

✍ Edward Wos; Thomas Olencki; Laurie Tuason; G. Thomas Budd; David Peereboom; Kate 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 465 KB 👁 2 views

## BACKGROUND. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a cytokine that is involved in the differentiation and proliferation of various hematopoietic precursors. It also has been reported to enhance the antitumor activity of various mature effector cells. Previous reports have

A phase II trial of interleukin-2 by con

A phase II trial of interleukin-2 by continuous infusion and interferon by intramuscular injection in patients with renal cell carcinoma

✍ A. Mittelman; C. Puccio; T. Ahmed; J. Zeffren; A. Choudhury; Z. Arlin 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 374 KB 👁 2 views

A phase II trial of interferon-α and 5-f

A phase II trial of interferon-α and 5-fluorouracil in patients with advanced renal cell carcinoma: A Southwest Oncology Group study

✍ Laurence Elias; Brent A. Blumenstein; Julie Kish; Robert C. Flanigan; James L. W 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 355 KB 👁 1 views

## BACKGROUND. Renal cell carcinoma is a common neoplasm that is often refractory to treatment. It is occasionally responsive to immunoniodulating agents including interferon-a, which enhances the effects of 5-fluorouracil upon cells. Combinations of these two drugs have been most frequently tested

Phase II trial of continuous once-daily

Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma

✍ Carlos H. Barrios; David Hernandez-Barajas; Michael P. Brown; Se-Hoon Lee; Luis 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 855 KB

A Phase II trial of intravenous gemcitab

A Phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-α in patients with metastatic renal cell carcinoma

✍ Christopher W. Ryan; Nicholas J. Vogelzang; Walter M. Stadler 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB 👁 2 views

## Abstract ## BACKGROUND The objective of this study was to determine the response rate and toxicity of gemcitabine and continuous‐infusion 5‐fluorouracil (5‐FU) in combination with subcutaneous interleukin‐2 (IL2) and interferon‐α (IFNA) in patients with metastatic renal cell carcinoma. ## METH